U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H18FN7O
Molecular Weight 415.423
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IDELALISIB

SMILES

CC[C@H](NC1=NC=NC2=C1N=CN2)C3=NC4=C(C(=O)N3C5=CC=CC=C5)C(F)=CC=C4

InChI

InChIKey=IFSDAJWBUCMOAH-HNNXBMFYSA-N
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H18FN7O
Molecular Weight 415.423
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Idelalisib is a first-in-class selective inhibitor of adenosine-5'-triphosphate (ATP) binding to PI3Kdelta kinase, resulting in inhibition of the P13K signalling pathway in malignant B cells. The compound is approved for the treatment of several types of blood cancer. Idelalisib is intended to be used in combination with rituximab as second or subsequent line therapy for the treatment of chronic lymphocytic leukaemia. The drug may cause fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation.

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
2011 Jan 13
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
2013
Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.
2013 Jan
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
2013 Jun 15
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
2014 Mar 13
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
2014 May 29
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
2014 May 29
Clinical drug interaction profile of idelalisib in healthy subjects.
2015 Aug
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dose is 150 mg taken orally, twice daily
Route of Administration: Oral
In Vitro Use Guide
Treatment of primary CLL cells (n =14) co-cultured with HS5 stromal cells with 100 nM idelalisib results in decreased AKT phosphorylation and inhibition of BCR mediated signaling pathways.
Substance Class Chemical
Created
by admin
on Mon Oct 21 20:46:40 UTC 2019
Edited
by admin
on Mon Oct 21 20:46:40 UTC 2019
Record UNII
YG57I8T5M0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IDELALISIB
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
CAL-101
Code English
GS-1101
Code English
4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-((1S)-1-(1H-PURIN-6-YLAMINO)PROPYL)-
Systematic Name English
ZYDELIG
Brand Name English
IDELALISIB [INN]
Common Name English
5-FLUORO-3-PHENYL-2-((S)-1-(9H-PURIN-6-YLAMINO)-PROPYL)-3H-QUINAZOLIN-4-ONE
Systematic Name English
IDELALISIB [VANDF]
Common Name English
IDELALISIB [MI]
Common Name English
IDELALISIB [WHO-DD]
Common Name English
4(3H)-QUINAZOLINONE, 5-FLUORO-3-PHENYL-2-((1S)-1-(9H-PURIN-6-YLAMINO)PROPYL)-
Systematic Name English
IDELALISIB [USAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 405913
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
EMA ASSESSMENT REPORTS ZYDELIG (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
NCI_THESAURUS C129825
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
FDA ORPHAN DRUG 405813
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
WHO-ATC L01XX47
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
NDF-RT N0000175605
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
FDA ORPHAN DRUG 405613
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
FDA ORPHAN DRUG 412613
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
EMA ASSESSMENT REPORTS ZYDELIG (AUTHORIZED: LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL)
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
FDA ORPHAN DRUG 405713
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
EU-Orphan Drug EU/3/13/1160
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
FDA ORPHAN DRUG 347511
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
NCI_THESAURUS C2152
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
FDA ORPHAN DRUG 412513
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
Code System Code Type Description
DRUG BANK
DB09054
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
NDF-RT
N0000175082
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY Kinase Inhibitors [MoA]
RXCUI
1544460
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY RxNorm
MERCK INDEX
M11752
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
LactMed
870281-82-6
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
EVMPD
SUB126168
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
CAS
870281-82-6
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
NDF-RT
N0000190114
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
NCI_THESAURUS
C78825
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
WIKIPEDIA
Idelalisib
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
IUPHAR
6741
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
INN
9624
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
ChEMBL
CHEMBL2216870
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
PUBCHEM
11625818
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
NCI_THESAURUS
C78825
Created by admin on Mon Oct 21 20:46:40 UTC 2019 , Edited by admin on Mon Oct 21 20:46:40 UTC 2019
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
TARGET->WEAK INHIBITOR
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
IC50
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC